Cardiovascular Device Liability Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Research results from M. Martino and co-authors update knowledge of adverse drug reactions
October 4th, 2009
"Healthy donors (HDs) who were mobilized using lenograstim (LENO) and who were undergoing peripheral haematopoietic progenitor cell collection with apheresis (HPC-A) were enrolled in a surveillance protocol. In all, 184 HDs have been assessed with a median follow-up of 62 months (range 2-155)," scientists in Italy report. "HDs received LENO at a median dose of 10 mu g/kg (range 5-15). Bone pain was reported as the most frequent short-term adverse event (71.2%). Other commonly observed short-term symptoms included fatigue (19.0%), fever (5.4%), headache (27.7%), nausea (12.0%) and insomnia (22.3%). Spleen size increased in 4.3% of the donors. No vascular disorders or...
Source: Cardiovascular Device Liability Week (2009-10-04)
|
